Title:
ENGINEERED IMMUNE CELL AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/238877
Kind Code:
A1
Abstract:
An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.
Inventors:
XING YUN (CN)
YAN ZHONGHUI (CN)
XIOGN YING (CN)
PU RONGRONG (CN)
REN JIANGTAO (CN)
HE XIAOHONG (CN)
WANG YANBIN (CN)
HAN LU (CN)
YAN ZHONGHUI (CN)
XIOGN YING (CN)
PU RONGRONG (CN)
REN JIANGTAO (CN)
HE XIAOHONG (CN)
WANG YANBIN (CN)
HAN LU (CN)
Application Number:
PCT/CN2021/095556
Publication Date:
December 02, 2021
Filing Date:
May 24, 2021
Export Citation:
Assignee:
NANJING BIOHENG BIOTECH CO LTD (CN)
International Classes:
C12N15/867; A61K35/17; A61K39/00; A61P31/00; A61P35/00; A61P37/02
Domestic Patent References:
| WO2006020258A2 | 2006-02-23 | |||
| WO2007024715A2 | 2007-03-01 |
Foreign References:
| CN111849910A | 2020-10-30 | |||
| CN108866003A | 2018-11-23 | |||
| CN109153989A | 2019-01-04 | |||
| CN108064176A | 2018-05-22 | |||
| US20180021253A1 | 2018-01-25 | |||
| CN111163758A | 2020-05-15 | |||
| CN109153989A | 2019-01-04 | |||
| US20050100543A1 | 2005-05-12 | |||
| US20050175606A1 | 2005-08-11 | |||
| US20070014794A1 | 2007-01-18 |
Other References:
ALFONSO R. SÁNCHEZ-PAULETE, ÁLVARO TEIJEIRA, JOSÉ I. QUETGLAS, MARÍA E. RODRÍGUEZ-RUIZ, ÁLVARO SÁNCHEZ-ARRÁEZ, SARA LABIANO, IÑAKI: "Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell–Mediated T-cell Cross-Priming.", CANCER RESEARCH, vol. 78, no. 23, 1 December 2018 (2018-12-01), US, pages 6643 - 6654, XP055871464, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-18-0933
ADACHI, K.KANO, Y.NAGAI, T. ET AL.: "IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor", NAT BIOTECHNOL, vol. 36, 2018, pages 346 - 351, XP055474269, DOI: 10.1038/nbt.4086
HOLLINGER, PROC NATL ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
SMITH, J. MOL. BIOL., vol. 147, 1981, pages 195 - 197
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
See also references of EP 4089174A4
ADACHI, K.KANO, Y.NAGAI, T. ET AL.: "IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor", NAT BIOTECHNOL, vol. 36, 2018, pages 346 - 351, XP055474269, DOI: 10.1038/nbt.4086
HOLLINGER, PROC NATL ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
SMITH, J. MOL. BIOL., vol. 147, 1981, pages 195 - 197
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
See also references of EP 4089174A4
Attorney, Agent or Firm:
SUZHOU CREATOR PATENT AND TRADEMARK AGENCY LTD. (CN)
Download PDF: